Matching Items (5)
Filtering by
- All Subjects: Breast Cancer
- Creators: Compton, Carolyn
- Creators: Lake, Douglas
Description
Currently, the availability and quantity of electronic support tools that oncology health care providers have access too is not the issue, but rather the quality within these tools due to the lack of individualization that they provide. This paper is a modest attempt to suggest the creation of an electronic prediction support tool called the Invasive Ductal Carcinoma Treatment Timeline Predictor (IDCTTP): a tool intended to increase the individualization and quality of patient care by taking a full timeline approach at each patient’s treatment plan. By being specifically focused on treatment plans for patients with stage III invasive ductal carcinoma, a type of breast cancer, this tool will initiate the process of individualization. It will then increase patients’ quality of care further by providing each distinctive stage III IDC patient with a full timeline approach: producing an initial prediction for a treatment plan, a second predicted plan in case of recurrence, and an alternative prediction in case original treatments are unsuccessful. This tool will also consider additional components such as patients’ financial situations, the potential for modifying or opting out of treatment due to side effects, and the constant medical debate of efficacy versus toxicity. For each stage III IDC patient that uses the IDCTTP, the result will be an electronic prediction tool that can give her the support that she needs to make those difficult decisions regarding her breast cancer treatment plan.
ContributorsHuang, Sarah Michelle (Author) / Compton, Carolyn (Thesis director) / Bimonte-Nelson, Heather (Committee member) / School of Life Sciences (Contributor) / Barrett, The Honors College (Contributor)
Created2020-05
Description
With cancer rates increasing and affecting more people every year, I felt it was important to educate the younger generation about the potential factors that could put them at risk of receiving a cancer diagnosis later in life. I thought that this was important to do because most students, especially in rural communities, are not taught the factors that increase your risk of getting cancer in the future. This leads to students not having the tools to think about the repercussions that their actions can have in their distant future in regard to their risk of getting cancer. I went to six schools throughout the valley and the White Mountains of Arizona with differing education levels and demographics to provide them with prevention strategies that they could implement into their daily lives to reduce their risk of getting cancer in the future. Some of the schools had curriculums that included cancer and some of the factors that increase your risk, while others never mention what is happening biologically when a person has cancer. I introduced factors such as no smoking or tobacco use, diet, exercise, sunscreen use, avoiding alcohol, and getting screened regularly. While at each school, I discussed the importance of creating these healthy habits while they are young because cancer is a disease that comes from the accumulation of mutations that can begin occurring in their bodies even now. After my presentation, 98.6% of the 305 students who viewed my presentation felt like they had learned something from the presentation and were almost all willing to implement at least one of the changes into their daily lives.
ContributorsGoforth, Michelle Nicole (Author) / Compton, Carolyn (Thesis director) / Lake, Douglas (Committee member) / Popova, Laura (Committee member) / Dean, W.P. Carey School of Business (Contributor) / School of Molecular Sciences (Contributor) / Barrett, The Honors College (Contributor)
Created2020-05
Description
Cancer is an ever-relevant disease with many genetic, social, environmental, and behavioral risk factors. One factor which has been garnering interest is the impact of nutrition on cancer. As a disease process, cancer is primarily driven by an accumulation of genetic aberrations. Recent epidemiological, pre-clinical, and clinical studies have demonstrated various impacts of bioactive food molecules on the promotion or prevention of these oncogenic mutations. This work explores several of these molecules and their relation to cancer prevention and provides a sample meal plan, which highlights many additional molecules that are currently being studied.
ContributorsCurtin, Elise (Author) / Don, Rachael (Thesis director) / Compton, Carolyn (Committee member) / Barrett, The Honors College (Contributor) / School of Life Sciences (Contributor)
Created2022-05
Description
Breast cancer is the most common disease among women and the second most common disease worldwide, accounting for 2.09 million new cases of cancer diagnosis in 2018. It accounts for 11.6% of all cancer cases and is the leading cause of cancer mortality for women as well as the fourth cause of cancer death overall. HER2-positive breast cancer is distinguished as a distinct subtype of breast cancer by the overexpression of HER2, a specific protein found on the surface of cancer cells. Because targeted medicines precisely target the overexpression of the HER2 protein, the management of HER2-positive breast cancer has undergone a complete revolution. Monoclonal antibodies targeting the extracellular domain of the HER2 protein were regarded to be a step forward in the treatment of breast cancer; however, affibody-DNA nanoparticles in particular offer a paradigm-shifting picture of cancer treatment and diagnostics. The advantages of affibody DNA nanoparticles include targeted distribution, customization, small size, potential for combination therapy, and unique character. These attributes make them a promising alternative to monoclonal antibodies, the current standard therapy, in the treatment of HER2 positive breast cancer. The purpose of this paper is to provide information on the most promising recently developed nanoparticle-based therapies for the diagnosis and management of HER-2-positive breast cancer.
ContributorsAndreyeva, Anastasiya (Author) / Chen, Shengxi (Thesis director) / Lake, Douglas (Committee member) / Barrett, The Honors College (Contributor) / College of Health Solutions (Contributor) / School of Art (Contributor)
Created2024-05
Description
Extracellular vesicles (EVs) represent a heterogeneous population of small vesicles, consisting of a phospholipidic bilayer surrounding a soluble interior cargo. These vesicles play an important role in cellular communication by virtue of their protein, RNA, and lipid content, which can be transferred among cells. Peripheral blood is a rich source of circulating EVs. An analysis of EVs in peripheral blood could provide access to unparalleled amounts of biomarkers of great diagnostic, prognostic as well as therapeutic value. In the current study, a plasma EV enrichment method based on pluronic co-polymer was first established and characterized. Plasma EVs from breast cancer patients were then enriched, profiled and compared to non-cancer controls. Proteins signatures that contributed to the prediction of cancer samples from non-cancer controls were created by a random-forest based cross-validation approach. We found that a large portion of these signatures were related to breast cancer aggression. To verify such findings, KIAA0100, one of the features identified, was chosen for in vitro molecular and cellular studies in the breast cancer cell line MDA-MB-231. We found that KIAA0100 regulates cancer cell aggression in MDA-MB-231 in an anchorage-independent manner and is particularly associated with anoikis resistance through its interaction with HSPA1A. Lastly, plasma EVs contain not only individual proteins, but also numerous molecular complexes. In order to measure millions of proteins, isoforms, and complexes simultaneously, Adaptive Dynamic Artificial Poly-ligand Targeting (ADAPT) platform was applied. ADAPT employs an enriched library of single-stranded oligodeoxynucleotides to profile complex biological samples, thus achieving a deep coverage of system-wide, native biomolecules. Profiling of EVs from breast cancer patients was able to obtain a prediction AUC performance of 0.73 when compared biopsy-positive cancer patient to healthy controls and 0.64 compared to biopsy-negative controls and such performance was not associated with the physical breast condition indicated by BIRAD scores. Taken together, current research demonstrated the potential of profiling plasma EVs in searching for therapeutic targets as well as diagnostic signatures.
ContributorsZhong, Zhenyu (Author) / Spetzler, David (Thesis advisor) / Yan, Hao (Thesis advisor) / Lake, Douglas (Committee member) / Mangone, Marco (Committee member) / Arizona State University (Publisher)
Created2018